ASH 2022 | AQUARIUS: investigating the safety of D-VCd in patients with newly diagnosed AL amyloidosis
In this video, Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, describes the ongoing Phase II AQUARIUS trial, which is evaluating the efficacy of daratumumab plus bortezomib, cyclophosphamide and dexamethasone (D-VCd) in patients with newly diagnosed light chain (AL) amyloidosis (NCT05250973). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
AQUARIUS is an ongoing study, which is trying to evaluate the efficacy of what has already been approved for the treatment of AL amyloidosis, the combination of daratumumab with VCd. This will also explore the toxicity of daratumumab versus daratumumab-VCd. So patients will start with daratumumab followed by VCd or with daratumumab-VCd, and we’ll explore whether there is any signal of cardiac toxicity from daratumumab...
AQUARIUS is an ongoing study, which is trying to evaluate the efficacy of what has already been approved for the treatment of AL amyloidosis, the combination of daratumumab with VCd. This will also explore the toxicity of daratumumab versus daratumumab-VCd. So patients will start with daratumumab followed by VCd or with daratumumab-VCd, and we’ll explore whether there is any signal of cardiac toxicity from daratumumab. I think this will be a very positive study and also will explore the efficacy of this combination in minorities. So this is also an ongoing study, and of course we do not have any results yet.
Read more...
Disclosures
GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
